OBJECTIVES: Demonstrate the cost benefits of the ready-to-use solution of midazolam (MRTU). According to the literature review, the failure caused by administrating drug errors represents 34,8% of adverse events in the hospital environment. Therefore, the ready-to-use solution could be an alternative to minimize the risks and errors.

METHODS: It was considering costs of anesthesia with midazolam using midazolam ready-to-use (MRTU) or conventional midazolam IV (MIV)ç (patient with a weight of 70kg - 100 mg/dose), adverse effects caused by administration failure, consumption of inputs, and labor; All these outcomes were based on bibliographic reviews and Brazilian official price lists (2022 values). The perspective is the private Brazilian health system.

RESULTS: Based on the cost of dose consumption of drugs, supplies, labor, and adverse events, the customary charge for using each MRTU was: BRL 75, with MIV 104. However, when analyzing the adverse events isolated caused by failures, the saving with MRTU was 2,479, and the return on investment with MRTU can be BRL 34 per dose.

CONCLUSIONS: With more economic savings/cost-benefit, the ready-to-use use of midazolam can reach BRL 28, or 27%. In addition, it reduces the consumption of labor time by 50%, 14% of death, 66% of occupation accidents, and 71% of waste. Meanwhile, MIV was the most expensive. The most appropriate treatment can reduce the likelihood of complications from adverse effects and the length of hospital stay—consequently, better hospital financial results and patient quality of life.